Overall Economic Summary
Today’s market opens on a two-speed macro backdrop: AI-driven earnings momentum is accelerating while geopolitical stress is spiking commodity costs. Palantir’s record Q1 blowout — 85% revenue growth, US business up 104% year-over-year, Rule of 40 score of 145% — validates that enterprise AI adoption is entering a vertical phase. This is the clearest signal yet that AI capital expenditure is not cooling. The PLTR result cements the AI infrastructure supercycle narrative that has driven semiconductors, cloud, and data center names for the past 18 months.
On the macro side, WTI crude is surging +2.12% to $104.10 on renewed Middle East tensions as the US-Iran standoff threatens to disrupt the Strait of Hormuz. A fragile ceasefire remains in doubt per Reuters. This creates a dual pressure on equity sentiment: energy bulls get a tailwind, but broader risk assets face an inflation re-acceleration threat if crude sustains above $100. The 10-year yield ticking up to 4.40% reflects this tension — modest re-pricing of the “soft landing” narrative.
The stablecoin legislation breakthrough is today’s secondary macro catalyst for crypto-adjacent equities. A bipartisan CLARITY Act compromise was reached, resolving the sticking point around stablecoin yield. Polymarket odds for the bill becoming law in 2026 jumped to 61%. This is regulatory legitimacy arriving for the stablecoin ecosystem — a direct catalyst for CRCL, COIN, and HOOD. Key risk events today: AMD Q1 earnings after close (the most important semi print since NVDA’s last quarter), and MSTR Q1 earnings (covers Bitcoin’s most volatile quarter).
Sources: BusinessWire (PLTR Q1), Reuters Morning Bid, Bloomberg Morning Brief, Reuters Newsletter (futures), CoinCentral (CLARITY Act), Stocktitan (AMD)
Top 5 Movers ▲ BULLISH REGIME — LONG SETUPS ONLY
Healthcare · Biotech | Pre-mkt Vol: 1,834K (avg ~est., 4.36× rel.) | ATR: $2.66 | Float: ~123M est. | Mkt Cap: $8.13B
NOTE: Gap exceeds the standard ±15% filter. Included as a hard binary catalyst exception — Phase 3 data is the definition of a catalyst play.
CATALYST
ACACIA-HCM Phase 3 trial results released pre-market: aficamten met BOTH dual primary endpoints (KCCQ-CSS symptom score AND pVO2 maximal exercise performance vs. placebo at Week 36). This is the most positive binary catalyst outcome possible for a pivotal trial. Additionally, today is Q1 earnings day (AMC) — first quarter of commercial MYQORZO sales data. Nine presentations confirmed at ESC Heart Failure 2026 Congress (May 9–12). Analyst upgrades following MYQORZO approval are reshaping the risk/reward narrative.
WHY IT’S MOVING
A pivotal Phase 3 success in a rare cardiac disease with high unmet need is the highest-conviction biotech catalyst. MYQORZO (aficamten’s predecessor compound) already received FDA approval, establishing commercial infrastructure. A SECOND successful Phase 3 expands the addressable population dramatically. Institutional buyers are chasing — pre-market volume of 1.83M shares at 4.36× relative volume confirms serious institutional participation, not retail noise. The gap exceeds +15% but this is a true data event, not a gap on thin volume or vague news.
KEY DAILY PRICE LEVELS
VWAP anchor: ~$64.50 (watch for 5-min VWAP reclaim as long trigger). Prior close: ~$53.83. 20-day MA: ~est. $52. ATR(14): $2.66. Opening range: Expect a wide 5-min ORB given the gap magnitude — wait for ORB high break on elevated volume for continuation. Bias: Long — $65 hold and VWAP reclaim targets $70, $75 measured move.
SUPPORT & RESISTANCE
Support: $62.50 (intraday pre-mkt low area), $59.50 (first gap-fill magnet), $53.83 (prior close — full gap fill only on trial data reversal). Resistance: $70.00 (psychological round), $75.00 (measured extension), $80.00 (potential new 52wk high zone).
WYCKOFF PHASE
Markup Phase — aggressive gap expansion following a Phase E Spring event. The Phase 3 data IS the cause-building completion event.
Sources: GlobeNewswire (ACACIA-HCM results), StockTitan (CYTK), TipRanks, SimplyWallSt — TradingView scanner CSV (May 5, 2026)
Bitcoin Proxy | Pre-mkt Vol: 316K (1.76× rel.) | ATR: $9.97 | Float: ~est. large | Mkt Cap: $63.6B
CATALYST
Dual catalyst today: (1) CLARITY Act stablecoin bill compromise boosts the entire crypto ecosystem’s legitimacy — Bitcoin proxies rally in sympathy. (2) Q1 2026 earnings after close tonight. Strategy holds 818,334 BTC at an average cost of $75,532/coin. With BTC trading ~$78K, the treasury shows unrealized gains. Saylor paused Bitcoin purchases ahead of earnings, which may signal a fresh purchase announcement post-print as a positive catalyst.
WHY IT’S MOVING
MSTR is the highest-beta leveraged Bitcoin proxy in the equity market. On days when the crypto regulatory environment improves (CLARITY Act), MSTR amplifies the BTC move by 2-3× due to its leverage structure and retail/institutional following. Pre-market +3.13% vs. BTC flat-to-slight positive suggests the CLARITY Act is the dominant driver today, not BTC price alone. Regime alignment: BULLISH, long bias, Bitcoin proxy names lead in growth-first environments.
KEY DAILY PRICE LEVELS
VWAP anchor: ~$182.50. Prior close: ~$178.20. 20-day MA: ~est. $175. ATR(14): $9.97. Bias: Long — breakout above $187 targets $190, $200 round number. Pre-earnings long carries risk of “sell the news” post-AMC print.
SUPPORT & RESISTANCE
Support: $178.20 (prior close), $172 (recent consolidation base), $165 (key structural support). Resistance: $187 (pre-mkt high zone), $190 (round number), $200 (major psychological).
WYCKOFF PHASE
Reaccumulation — BTC building cause at $78K range; MSTR mirroring with tight pre-earnings consolidation.
Sources: CoinDesk (MSTR holdings), Cryptonomist (earnings preview), Strategy.com, WebSearch — TradingView scanner CSV
Crypto / Stablecoin Infrastructure | Pre-mkt Vol: 928K (1.57× rel.) | ATR: $8.55 | Float: ~est. | Mkt Cap: $29.5B
CATALYST
The CLARITY Act stablecoin bill reached a bipartisan breakthrough over the weekend. Senators Tillis and Alsobrooks released compromise text resolving the sticking point on stablecoin yield (passive yield banned; activity-based rewards allowed). This is existential regulatory clarity for Circle, the issuer of USDC — the world’s second-largest stablecoin. Committee markup could come as early as May 11; full Senate floor vote possible June–July. Separately, Meta announced USDC-based creator compensation on Solana and Polygon, and Visa expanded blockchain stablecoin infrastructure — all directly validating USDC’s ecosystem role. CRCL also surged 18% on May 4 and continues today.
WHY IT’S MOVING
Circle is the direct, pure-play beneficiary of stablecoin regulation in the US. USDC is Circle’s core product — regulatory clarity transforms USDC from a “tolerated” asset to a legally recognized payment instrument. This dramatically expands the addressable market: banks can now integrate USDC, institutional flows accelerate, and Circle’s revenue model (interest on USD reserves backing USDC) benefits from sustained high rates. Multi-day momentum with volume confirms institutional buying, not just retail hype.
KEY DAILY PRICE LEVELS
VWAP anchor: ~$118. Prior close: ~$114.56. ATR(14): $8.55. Bias: Long — $115 is the key intraday floor (prior close). ORB breakout above $122 targets $125, $130 on legislative continuation catalyst. Note: stock is down 67% from its 52-week high, so there is overhead supply risk from prior holders.
SUPPORT & RESISTANCE
Support: $115.00 (prior close / VWAP anchor), $110 (prior consolidation), $105 (key structural). Resistance: $122 (pre-mkt session high), $125 (round), $130 (measured move from CLARITY catalyst level).
Sources: MEXC News / CoinCentral / MoneyCheck (CLARITY Act), StockObserver (CRCL gap), Tikr.com — TradingView scanner CSV
Semiconductor / AI GPU | Pre-mkt Vol: 549K (1.47× rel.) | ATR: $16.32 | Float: large-cap | Mkt Cap: $556.8B
CATALYST
AMD reports Q1 2026 earnings after the close tonight — consensus at $9.89B revenue (+33% YoY) and $1.29 EPS (+34% YoY). Pre-print catalysts piling up: Meta’s massive multi-year 6-gigawatt AMD GPU deal, TSMC Q1 revenue +35% YoY validating insatiable AI chip demand, Goldman Sachs named AMD a top pick ahead of earnings, Citi placed the stock on 30-day positive catalyst watch. The UALink open accelerator standard — AMD’s open alternative to NVIDIA NVLink — was formally approved. AMD gained 74% in April, demonstrating that the market is already pricing in secular AI GPU demand.
WHY IT’S MOVING
AMD is the #2 GPU player in an AI race where demand is growing faster than supply. The hyperscaler diversification trade — Microsoft, Meta, Google reducing NVIDIA concentration risk by qualifying AMD MI-series GPUs — is the structural story. Pre-market volume of 549K (highest absolute volume of non-biotech names on the scanner) at $341 per share means serious dollar volume is changing hands. Palantir’s blowout quarter this morning further validates enterprise AI capital spending, which flows directly into AMD’s GPU/AI accelerator business.
KEY DAILY PRICE LEVELS
VWAP anchor: ~$340. Prior close: ~$334.22. 20-day MA: ~est. $280 (given the April 74% surge). ATR(14): $16.32. Bias: Long pre-earnings accumulation — hold through close for earnings play OR take pre-earnings long for opening range breakout. High risk: earnings result tonight could cause big move in either direction. If holding through earnings, $320 stop is generous.
SUPPORT & RESISTANCE
Support: $334 (prior close/PM base), $325 (key intraday), $310 (structural support zone from April breakout). Resistance: $350 (round number/near-term target), $360 (pre-earnings high zone), $380 (measured move if beats big tonight).
WYCKOFF PHASE
Reaccumulation — April’s 74% vertical markup created a new accumulation range. Pre-earnings positioning is the cause-building phase for the next potential leg.
Sources: Motley Fool (AMD +74% April), AlphaStreet (AMD Q1 preview), Yahoo Finance (Goldman top pick), Stocktitan (UALink) — TradingView scanner CSV
Crypto Exchange / Fintech | Pre-mkt Vol: 300K (1.62× rel.) | ATR: $11.66 | Float: large-cap | Mkt Cap: $53.6B
CATALYST
CLARITY Act stablecoin legislation is a direct positive for Coinbase on two fronts: (1) Coinbase is the primary USDC distribution partner with Circle — regulatory clarity for USDC is regulatory clarity for Coinbase’s stablecoin revenue stream. (2) As the largest US crypto exchange, any legislation that legitimizes digital assets expands Coinbase’s potential customer base, institutional partnerships, and trading volumes. Broader crypto market strength (BTC ~$78K) is a second tailwind.
WHY IT’S MOVING
Coinbase is the liquid, publicly traded vehicle for US crypto exposure. When stablecoin legislation advances, Coinbase benefits both operationally and as a proxy for institutional confidence in crypto regulation. The stock’s move to $202.99 (+3.74%) represents a clean breakout above the $200 psychological level — a level that has been key resistance for months. With CRCL, MSTR, and HOOD all moving in sympathy, the crypto theme has broad internal breadth today. Coinbase provides the most liquid access to this theme for institutional traders.
KEY DAILY PRICE LEVELS
VWAP anchor: ~$200. Prior close: ~$195.67. ATR(14): $11.66. Bias: Long — $200 breakout and hold is the setup. First target $210 (round), second $220 (measured move). Tight stop below $197 (pre-market base / prior close).
SUPPORT & RESISTANCE
Support: $200 (breakout retest level / psychological), $195.67 (prior close), $188 (prior support zone). Resistance: $210 (round number / near-term target), $220 (measured move), $230 (upper channel extension).
WYCKOFF PHASE
Markup Phase — CLARITY Act catalyst acts as a Sign of Strength (SOS) push through prior resistance at $200.
Sources: CoinCentral / MoneyCheck (CLARITY Act Coinbase impact), WebSearch composite — TradingView scanner CSV
Research Themes
🤖 Theme 1: The AI Infrastructure Supercycle — Palantir Validates the Next Phase
Palantir’s Q1 blowout — 85% total revenue growth, US commercial up 133% YoY, Rule of 40 score of 145% — is the single most important earnings result of the year so far for AI infrastructure bulls. It confirms that AI spending is not consolidating; it is accelerating into a vertical phase. Enterprise AI adoption is crossing the chasm from “pilot projects” to “production systems,” and PLTR is the purest proxy for that transition. The AMD earnings tonight will be the next data point: if AMD confirms AI GPU demand is still insatiable (Meta’s 6-GW deal being the indicator), expect a fresh leg higher in the semiconductor ecosystem starting May 6. Micron (MU) and NVIDIA (NVDA) benefit from any AMD beat given shared demand dynamics.
Watch: AMD (earnings), PLTR, NVDA, MU, MRVL, ANET, CRWV, DELL
Sources: BusinessWire (PLTR Q1), AlphaStreet (AMD preview), Reuters Morning Bid “AI binge”
🪙 Theme 2: Stablecoin Regulatory Legitimacy — CLARITY Act Breakthrough
The bipartisan CLARITY Act compromise is the most significant crypto regulatory development of 2026. By resolving the stablecoin yield question, it opens the door for banks, payment processors, and fintech companies to legally integrate USDC and other regulated stablecoins into mainstream financial infrastructure. Polymarket odds jumped to 61% for passage. The immediate beneficiaries are the stablecoin ecosystem (CRCL), crypto exchanges (COIN), retail trading platforms with crypto exposure (HOOD), and Bitcoin proxies (MSTR). Longer-term, this regulatory clarity could unlock institutional Bitcoin ETF flows and further legitimize the crypto asset class. Watch for any Senate scheduling news this week and the May 11 committee markup.
Watch: CRCL, COIN, MSTR, HOOD, RIOT, MARA, IREN
Sources: CoinCentral, MEXC News, MoneyCheck (CLARITY Act bipartisan deal)
💊 Theme 3: Cytokinetics — Biotech Binary Catalyst with Commercial Tail
CYTK’s ACACIA-HCM Phase 3 success creates a two-part trade opportunity. The immediate trade is the gap play on today’s data — aficamten works in non-obstructive HCM, dramatically expanding the patient population beyond MYQORZO’s existing indication. The longer-term thesis is the commercial trajectory of MYQORZO: today’s Q1 earnings call will deliver the first sales data for a newly approved rare cardiac drug with no effective competition in the non-obstructive HCM space. Nine ESC presentations next week (May 9–12) will drive continued institutional attention. Biotech names with hard catalyst + commercial launch + follow-on trial success are rare — CYTK checks all three boxes today.
Watch: CYTK (primary), sector context: RXRX, BBAI (AI biotech plays)
Sources: GlobeNewswire, StockTitan, TipRanks (CYTK catalyst coverage)